Psittacosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
(2 intermediate revisions by 2 users not shown) | |||
Line 9: | Line 9: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Pulmonology]] | |||
[[Category:Zoonoses]] | |||
[[Category:Bacterial diseases]] | |||
[[Category:Infectious diseases]] | |||
[[Category:Disease]] | |||
[[Category:Emergency mdicine]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] |
Latest revision as of 23:51, 29 July 2020
Psittacosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Psittacosis future or investigational therapies On the Web |
American Roentgen Ray Society Images of Psittacosis future or investigational therapies |
Risk calculators and risk factors for Psittacosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]
Overview
Future
- Future challenges lay in the rigorous reporting of infections in both poultry and poultry workers and in the development of an avian and human vaccine.[1]
- Use of ovotransferrin as anitmicrobial in poultry to reduce dissemination of bacteria into air. [2]
References
- ↑ Deschuyffeleer TP, Tyberghien LF, Dickx VL; et al. (2012). "Risk assessment and management of Chlamydia psittaci in poultry processing plants". Ann Occup Hyg. 56 (3): 340–9. doi:10.1093/annhyg/mer102. PMID 22302240. Unknown parameter
|month=
ignored (help) - ↑ Van Droogenbroeck C, Dossche L, Wauman T; et al. (2011). "Use of ovotransferrin as an antimicrobial in turkeys naturally infected with Chlamydia psittaci, avian metapneumovirus and Ornithobacterium rhinotracheale". Vet. Microbiol. 153 (3–4): 257–63. doi:10.1016/j.vetmic.2011.05.016. PMID 21885218. Unknown parameter
|month=
ignored (help)